Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    X4P-001-RD

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    X4 Pharma Heads to NASDAQ Via Reverse Merger with Arsanis
    X4 Pharma Heads to NASDAQ Via Reverse Merger with Arsanis

    28 Nov 2018

    // Ben Fidler XCONOMY

    https://xconomy.com/boston/2018/11/27/x4-pharma-heads-to-nasdaq-via-reverse-merger-with-arsanis/

    Ben Fidler XCONOMY
    28 Nov 2018
    Share Share
    X4 Pharma to Report Clinical Biomarker Data X4P-001 at the Upcoming 2018 (AACR)
    X4 Pharma to Report Clinical Biomarker Data X4P-001 at the Upcoming 2018 (AACR)

    07 May 2018

    // PRESS RELEASE

    http://www.x4pharma.com/news/x4-pharmaceuticals-report-clinical-biomarker-data-x4p-001-upcoming-2018-american-association-cancer-research-aacr-annual-meeting/

    PRESS RELEASE
    07 May 2018
    Share Share
    X4 Pharmaceuticals Secures $27 Million in Series B Financing
    X4 Pharmaceuticals Secures $27 Million in Series B Financing

    16 Nov 2017

    // PRESS RELEASE

    http://www.x4pharma.com/news/x4-pharmaceuticals-secures-27-million-series-b-financing/

    PRESS RELEASE
    16 Nov 2017
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.